Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib - Pfizer

Drug Profile

Tofacitinib - Pfizer

Alternative Names: Cp-690,550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Xeljanz; Xeljanz XR

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Oregon Health & Science University; Pfizer; University of Michigan
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase III Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis
  • Phase II Atopic dermatitis
  • Phase I/II Diffuse scleroderma
  • Phase I Dermatomyositis; Pulmonary sarcoidosis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 25 Nov 2019 Updated efficacy data from a phase III OCTAVE long-term extension trial in presented at the Digestive Disease Week 2019 (DDW-2019)
  • 15 Nov 2019 University of Michigan completes a phase I/II trial in Diffuse scleroderma in USA (NCT03274076)
  • 13 Nov 2019 Pfizer completes enrolment in its phase III OCTAVE long-term extension trial for Ulcerative Colitis in Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, New Zealand, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom and USA (NCT01470612)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top